Physician profile
Robert G Bulten
NPI 1023177268
$3,103.32
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $759 · 2021: $1,108 · 2022: $664 · 2023: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,093.68 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $791.41 | 2019-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $376.17 | 2021-2022 | |
| Lundbeck LLC | $245.82 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $178.90 | 2021-2022 | |
| Tris Pharma INC | $177.47 | 2019-2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $81.18 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $44.76 | 2019 | |
| Allergan, INC. | $29.99 | 2019 | |
| Shire North American Group INC | $24.85 | 2019 | |
| Axsome Therapeutics, INC. | $16.23 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.58 | 2019 | |
| Corium, LLC | $14.32 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bulten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.